NZ613111B2 - Citrate free pharmaceutical compositions comprising anakinra - Google Patents
Citrate free pharmaceutical compositions comprising anakinra Download PDFInfo
- Publication number
- NZ613111B2 NZ613111B2 NZ613111A NZ61311112A NZ613111B2 NZ 613111 B2 NZ613111 B2 NZ 613111B2 NZ 613111 A NZ613111 A NZ 613111A NZ 61311112 A NZ61311112 A NZ 61311112A NZ 613111 B2 NZ613111 B2 NZ 613111B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- anakinra
- pharmaceutical formulation
- formulation according
- mannitol
- amount
- Prior art date
Links
- 229960004238 anakinra Drugs 0.000 title claims abstract description 108
- HMLGSIZOMSVISS-ONJSNURVSA-N (7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 title claims abstract description 106
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 47
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 title claims abstract description 12
- 239000000203 mixture Substances 0.000 claims abstract description 77
- 201000010099 disease Diseases 0.000 claims abstract description 29
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 25
- 102000000589 Interleukin-1 Human genes 0.000 claims abstract description 23
- 108010002352 Interleukin-1 Proteins 0.000 claims abstract description 23
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 claims abstract description 21
- 239000000594 mannitol Substances 0.000 claims abstract description 21
- 235000010355 mannitol Nutrition 0.000 claims abstract description 21
- 230000001404 mediated Effects 0.000 claims abstract description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 38
- 239000007924 injection Substances 0.000 claims description 26
- 238000002347 injection Methods 0.000 claims description 24
- 238000009472 formulation Methods 0.000 claims description 21
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 20
- 239000011780 sodium chloride Substances 0.000 claims description 19
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 13
- 239000010452 phosphate Substances 0.000 claims description 12
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 12
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 12
- 229920000053 polysorbate 80 Polymers 0.000 claims description 12
- 229940068968 Polysorbate 80 Drugs 0.000 claims description 11
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 11
- 239000007929 subcutaneous injection Substances 0.000 claims description 11
- 239000006172 buffering agent Substances 0.000 claims description 10
- 239000001488 sodium phosphate Substances 0.000 claims description 10
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 10
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 10
- 238000010254 subcutaneous injection Methods 0.000 claims description 9
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims description 6
- 239000007979 citrate buffer Substances 0.000 claims description 6
- 208000001294 Nociceptive Pain Diseases 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000002738 chelating agent Substances 0.000 claims description 3
- 239000003995 emulsifying agent Substances 0.000 claims description 3
- 206010003246 Arthritis Diseases 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 150000002016 disaccharides Chemical class 0.000 claims description 2
- 150000002772 monosaccharides Chemical class 0.000 claims description 2
- 239000002736 nonionic surfactant Substances 0.000 claims description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 23
- 239000001509 sodium citrate Substances 0.000 description 23
- 239000011778 trisodium citrate Substances 0.000 description 23
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 17
- 239000000243 solution Substances 0.000 description 14
- 230000000694 effects Effects 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 239000002245 particle Substances 0.000 description 10
- 210000000138 Mast Cells Anatomy 0.000 description 9
- 230000002776 aggregation Effects 0.000 description 9
- 238000004220 aggregation Methods 0.000 description 9
- 239000000178 monomer Substances 0.000 description 9
- NTYJJOPFIAHURM-UHFFFAOYSA-N histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 8
- 238000001542 size-exclusion chromatography Methods 0.000 description 8
- 210000002683 Foot Anatomy 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 7
- 229940079593 drugs Drugs 0.000 description 7
- 230000036407 pain Effects 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 230000001154 acute Effects 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000001690 micro-dialysis Methods 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 5
- 210000003491 Skin Anatomy 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 208000004454 Hyperalgesia Diseases 0.000 description 4
- 208000007999 Hyperesthesia Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 206010021972 Inflammatory bowel disease Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000005755 formation reaction Methods 0.000 description 4
- 210000000548 hind-foot Anatomy 0.000 description 4
- 229960001340 histamine Drugs 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 206010022095 Injection site reaction Diseases 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 210000004027 cells Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 230000020341 sensory perception of pain Effects 0.000 description 3
- 230000001225 therapeutic Effects 0.000 description 3
- 210000001519 tissues Anatomy 0.000 description 3
- 208000002496 Adult-Onset Still's Disease Diseases 0.000 description 2
- 208000006673 Asthma Diseases 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- 208000001591 Cryopyrin-Associated Periodic Syndrome Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- KBNIFDASRCWYGC-GXNXWABVSA-J Evans blue Chemical compound [Na+].[Na+].[Na+].[Na+].C\1=CC2=C(S([O-])(=O)=O)C=C(S([O-])(=O)=O)C(N)=C2C(=O)C/1=N/NC(C(C)=C1)=CC=C1C1=CC=C(N\N=C/2C(C3=C(N)C(=CC(=C3C=C\2)S([O-])(=O)=O)S([O-])(=O)=O)=O)C(C)=C1 KBNIFDASRCWYGC-GXNXWABVSA-J 0.000 description 2
- 206010072010 Hyper IgD syndrome Diseases 0.000 description 2
- 206010065390 Inflammatory pain Diseases 0.000 description 2
- 206010022114 Injury Diseases 0.000 description 2
- 108010023402 Interleukin 1 Receptor Antagonist Protein Proteins 0.000 description 2
- 102000016664 Interleukin-1 receptor antagonist Human genes 0.000 description 2
- 102000019223 Interleukin-1 receptor family Human genes 0.000 description 2
- 108050006617 Interleukin-1 receptor family Proteins 0.000 description 2
- 229940054136 Kineret Drugs 0.000 description 2
- 206010024324 Leukaemias Diseases 0.000 description 2
- 206010028549 Myeloid leukaemia Diseases 0.000 description 2
- 210000000929 Nociceptors Anatomy 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 101710009098 PLC7 Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229950008882 Polysorbate Drugs 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 206010053879 Sepsis syndrome Diseases 0.000 description 2
- 102000004338 Transferrin Human genes 0.000 description 2
- 108090000901 Transferrin Proteins 0.000 description 2
- 206010067774 Tumour necrosis factor receptor-associated periodic syndrome Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 102000004965 antibodies Human genes 0.000 description 2
- 108090001123 antibodies Proteins 0.000 description 2
- 239000008364 bulk solution Substances 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 239000012470 diluted sample Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 description 2
- 230000000302 ischemic Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 230000003040 nociceptive Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 201000004681 psoriasis Diseases 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 239000004627 regenerated cellulose Substances 0.000 description 2
- -1 sodium phosphate Chemical compound 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 201000010874 syndrome Diseases 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 206010000496 Acne Diseases 0.000 description 1
- 206010000501 Acne conglobata Diseases 0.000 description 1
- 210000000577 Adipose Tissue Anatomy 0.000 description 1
- 206010002023 Amyloidosis Diseases 0.000 description 1
- 206010002022 Amyloidosis Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000002399 Aphthous Stomatitis Diseases 0.000 description 1
- 208000009766 Blau syndrome Diseases 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- 210000001124 Body Fluids Anatomy 0.000 description 1
- DNKYDHSONDSTNJ-XJVRLEFXSA-N CHEMBL1910953 Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)N)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CN=CN1 DNKYDHSONDSTNJ-XJVRLEFXSA-N 0.000 description 1
- 102000004414 Calcitonin gene-related peptide Human genes 0.000 description 1
- 108090000932 Calcitonin gene-related peptide Proteins 0.000 description 1
- YKPUWZUDDOIDPM-SOFGYWHQSA-N Capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 1
- 208000005024 Castleman Disease Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 208000002849 Chondrocalcinosis Diseases 0.000 description 1
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 description 1
- 206010009869 Cold urticaria Diseases 0.000 description 1
- 210000002808 Connective Tissue Anatomy 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 210000004207 Dermis Anatomy 0.000 description 1
- 206010012601 Diabetes mellitus Diseases 0.000 description 1
- 102100004921 EDN1 Human genes 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N Endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 108010072834 Endothelin-1 Proteins 0.000 description 1
- 206010060801 Erdheim-Chester disease Diseases 0.000 description 1
- CYTYCFOTNPOANT-UHFFFAOYSA-N Ethylene tetrachloride Chemical compound ClC(Cl)=C(Cl)Cl CYTYCFOTNPOANT-UHFFFAOYSA-N 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 206010016207 Familial mediterranean fever Diseases 0.000 description 1
- 210000004700 Fetal Blood Anatomy 0.000 description 1
- 102100020039 HPGDS Human genes 0.000 description 1
- 101700056286 HPGDS Proteins 0.000 description 1
- 208000002557 Hidradenitis Diseases 0.000 description 1
- 206010048595 Histiocytosis haematophagic Diseases 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N Inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 Inositol Drugs 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 210000003734 Kidney Anatomy 0.000 description 1
- 206010024377 Leukocytoclastic vasculitis Diseases 0.000 description 1
- 206010024769 Local reaction Diseases 0.000 description 1
- 208000004987 Macrophage Activation Syndrome Diseases 0.000 description 1
- 208000009777 Majeed syndrome Diseases 0.000 description 1
- 206010072221 Mevalonate kinase deficiency Diseases 0.000 description 1
- 206010072219 Mevalonic aciduria Diseases 0.000 description 1
- 206010067115 Neutrophilic panniculitis Diseases 0.000 description 1
- 206010031149 Osteitis Diseases 0.000 description 1
- 241001425761 Parthenos sylvia Species 0.000 description 1
- 208000008494 Pericarditis Diseases 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- 206010065159 Polychondritis Diseases 0.000 description 1
- 208000005987 Polymyositis Diseases 0.000 description 1
- BHMBVRSPMRCCGG-OUTUXVNYSA-N Prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 description 1
- 206010037575 Pustular psoriasis Diseases 0.000 description 1
- 208000009954 Pyoderma Gangrenosum Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000009169 Relapsing Polychondritis Diseases 0.000 description 1
- 201000010848 Schnitzler syndrome Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 208000004346 Smoldering Multiple Myeloma Diseases 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- 101700065588 TAC1 Proteins 0.000 description 1
- 102000007238 Transferrin Receptors Human genes 0.000 description 1
- 108010033576 Transferrin Receptors Proteins 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N Trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000001072 Type 2 Diabetes Mellitus Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 210000003462 Veins Anatomy 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003042 antagnostic Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960000074 biopharmaceuticals Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 201000008975 bone inflammation disease Diseases 0.000 description 1
- 230000003139 buffering Effects 0.000 description 1
- 239000003710 calcium ionophore Substances 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 229930003833 capsaicin Natural products 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000004106 carminic acid Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- OLSDWRNWUGHKSY-UHFFFAOYSA-J dicalcium;phosphonato phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O OLSDWRNWUGHKSY-UHFFFAOYSA-J 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 201000010934 exostosis Diseases 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 102000037240 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 201000005569 gout Diseases 0.000 description 1
- 230000003394 haemopoietic Effects 0.000 description 1
- 201000007162 hidradenitis suppurativa Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 201000010930 hyperostosis Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 201000008319 inclusion body myositis Diseases 0.000 description 1
- 230000002757 inflammatory Effects 0.000 description 1
- 200000000018 inflammatory disease Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 102000002467 interleukin receptors Human genes 0.000 description 1
- 108010093036 interleukin receptors Proteins 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 201000003265 lymphadenitis Diseases 0.000 description 1
- 230000001537 neural Effects 0.000 description 1
- 108091008022 nociceptors Proteins 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000037324 pain perception Effects 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 101710005265 pgdP Proteins 0.000 description 1
- 201000007100 pharyngitis Diseases 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000069 prophylaxis Effects 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 230000000306 recurrent Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000020874 response to hypoxia Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 201000009295 smoldering myeloma Diseases 0.000 description 1
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulphite Substances [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
- 239000006076 specific stabilizer Substances 0.000 description 1
- 230000002269 spontaneous Effects 0.000 description 1
- 230000000087 stabilizing Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival Effects 0.000 description 1
- 230000002522 swelling Effects 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 231100000730 tolerability Toxicity 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/545—IL-1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
Abstract
Disclosed is a pharmaceutical composition comprising anakinra and mannitol, but no citrate. The mannitol is in an amount of 5-50 mg/ml. Also disclosed is the use of said composition to treat IL-1 mediated disorders.
Description
CITRATE FREE PHARMACEUTICAL COMPOSITIONS COMPRISING ANAKINRA
TECHNICAL FIELD
The present invention relates to pharmaceutical compositions comprising anakinra as an active
compound in the absence of sodium citrate. The said pharmaceutical compositions are useful for
the treatment of IL-1 mediated disorders and for decreasing nociceptive pain during such
treatment.
BACKGROUND ART
Pharmaceutical formulations suitable for parenteral delivery typically comprise (a) an active
molecule; (b) a buffering agent with sufficient buffering capacity to control solution pH; and (c)
a tonicity agent to provide isotonicity of the formulation. Additionally, further components may
be added such as antioxidants, specific stabilizers, surfactants, preservatives, etc., as needed
depending on the specific active and its intended use.
The selection of the formulation components has to be based on thorough studies evaluating
different components with respect to their function in the formulation and optimal stabilizing
capacity. Furthermore, other formulation studies have to be performed to identify other solution
parameters, such as optimal pH and ionic strength for the specific active molecule and its
intended use. Studies are also performed to optimize the concentrations of the respective
formulation components. In many cases, additional aspects of the final formulation and its
clinical use have to be considered, such as appropriate injection volume, compatibility with
physiological fluids or tissues, viscosity, local tolerance etc.
One example of local tolerance concerns the selection of buffer species. It is known that specific
buffer species may provoke local in-tolerance or injection pain. Sodium citrate has been reported
to cause pain upon subcutaneous injection in some cases (Frenken, 1993, Laursen, 2006). In
addition, buffer concentration should be minimized to be optimal with respect to not only to pH
stability in the drug formulation during long term storage, but also as having minimal impact on
the physiological conditions at the injection site (e.g. Fransson and Espander-Jansson, 1996).
The list of components that can be added to a formulation for parenteral delivery is limited
(Wang and Kowall, 1980; Nema, 2006). A number of aspects has to be considered; safety, prior
experience in humans, availability from suppliers, etc. The stability of protein drugs in vivo and
in vitro is a complex matter where multiple degradation reactions occur in parallel, such as
oxidation, deamidation, aggregation etc. One major reaction occurring is formation of
aggregates. Protein aggregates can form via covalent or non-covalent pathways, and can be of
soluble or insoluble nature. The presence of protein aggregates is a major concern from safety
perspective as it may impact the secondary and tertiary structure of the protein. Presence of
specific non-native protein structures has been associated with increased immunogenicity of
proteins potentially causing reduced efficacy or even in vivo immunological reactions to native
proteins, with life threatening conditions as result.
Interleukin-l mediated diseases include rheumatoid arthritis (RA), inflammatory bowel disease
(IBD), sepsis, sepsis syndrome, osteoporosis, ischemic injury, graft vs. host disease, reperfusion
injury, asthma, insulin diabetes, myelogenous and other leukemias, psoriasis and cachexia. These
and other inflammatory diseases are characterized by the production of cytokines, including
interleukin-l.
For those syndromes where a role for IL-1 in the pathology of the disease has been established,
the clinical manifestations of the disease can rapidly be alleviated by treatment with anti-IL-1
medicines. One such medicine is Kineret , whose active component, anakinra, is a recombinant
version of the naturally occurring IL-1 receptor antagonist (IL-1ra). Anakinra is disclosed in, e.g.
US 5,075,222.
Kineret (anakinra for injection) is formulated at 150 mg/ml with a 10 mM sodium citrate buffer
(pH 6-7) and sodium chloride (140 mM) as tonicity agent. Furthermore, 0.5 mM EDTA and 0.1
% (w/w) polysorbate 80 are used as stabilizers. The selection of sodium citrate as buffer
component for anakinra was based on detailed studies evaluating the short and long term
stability of anakinra at real time conditions. Several potential buffer components were evaluated,
sodium phosphate being one and sodium citrate was identified as providing the optimal stability
with respect to anakinra aggregation (Raibekas et al., 2005). Aggregation of anakinra was a
major concern for the selection of the buffer component. The concentration of the sodium citrate
was minimized as much as possible considering the local tolerability.
During clinical use of anakinra in 10 mM sodium citrate, it was found that the formulation
caused issues with local tolerance at the subcutaneous injection site (Thaler, 2009). Injection site
reactions are not uncommon with subcutaneous delivery of protein drugs and are a general
problem (Haller, 2008) and are associated with clinical use of a large number of protein drugs.
More than 50% of the patients using anakinra for injection experiences injection site reactions to
some degree for the first injections. The nature and the mechanism of local reaction have been
investigated and several conclusions have been made (Bendele, 1995). It has been concluded that
the injection site reaction has multiple causes including anakinra molecule itself and the
formulation components, sodium citrate having a very large impact.
Consequently, there is a need for anakinra compositions, suitable for injection, which are stable
and which avoid the drawbacks with anakinra compositions comprising sodium citrate, and/or
which at least provides the public with a useful choice.
In this specification where reference has been made to patent specifications, other external
documents, or other sources of information, this is generally for the purpose of providing a
context for discussing the features of the invention. Unless specifically stated otherwise,
reference to such external documents is not to be construed as an admission that such documents,
or such sources of information, in any jurisdiction, are prior art, or form part of the common
general knowledge in the art.
In the description in this specification reference may be made to subject matter that is not within
the scope of the claims of the current application. That subject matter should be readily
identifiable by a person skilled in the art and may assist in putting into practice the invention as
defined in the claims of this application.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows the number of sub-visible particles (larger than 5, 7.5 and 10 µm in size) per ml
of various anakinra compositions (designated E, G, H, O, R, S, T, and U).
Figure 2 shows the number of particles as in Figure 1, after the said anakinra compositions had
been stored for 1 month at +25°C.
Figure 3 shows the number of particles as in Figure 1, after the said anakinra compositions had
been stored for 3 months at +5°C.
Figure 4 indicates inflammation, as indicated by increased paw volume, in male Sprague-Dawley
rats after administration of various anakinra compositions.
DISCLOSURE OF THE INVENTION
According to the invention, it has surprisingly been shown that anakinra, suitable for injection,
can be sufficiently stabilized without the use of sodium citrate. In contrast to the findings by
Raibekas et al. (2005), anakinra can be formulated in aqueous solution with an appropriate
tonicity agent and additional stabilizers, but without sodium citrate as buffer. Under appropriate
preparation conditions, anakinra will inherently control the solution pH. Even a solution with no
added buffer may be sufficiently stable.
Consequently, in a first aspect the invention provides a pharmaceutical formulation comprising
an effective amount of anakinra, and mannitol in an amount from 5 to 50 mg/ml, wherein the
said pharmaceutical formulation is in the absence of citrate.
The invention also relates to a use of anakinra and mannitol, in the manufacture of a
pharmaceutical formulation suitable for injection for use in the treatment of IL-1 mediated
disorders, wherein: said pharmaceutical formulation is in the absence of citrate; anakinra is
present in the medicament in an effective amount; and mannitol is present in the medicament in
an amount from 5 to 50 mg/ml.
Also described is a method for the treatment or prevention of an IL-1 mediated disorder which
comprises administering to a mammal, including man, in need of such treatment a
pharmaceutical formulation comprising an effective amount of anakinra, wherein the said
pharmaceutical formulation does not contain citrate.
According to the invention the said formulation is stable in the absence of citrate, wherein the
term “stable” implies, for instance, that the absence of aggregation and/or pH stability is, at least,
approximately equal to a similar anakinra formulation comprising 10 mM sodium citrate (pH 6-
The term “anakinra” means, in particular, the IL-1 receptor antagonist (IL-1ra) having the 152
amino acid sequence shown as positions 26-177 in NCBI Reference Sequence NP_776214.1
(www.ncbi.nlm.nih.gov). Further, the term “anakinra” should be understood as including
modified forms of anakinra, e.g. amino acid variants having at least 90%, 95%, 97% or 99%
identity with the anakinra amino acid sequence. The person skilled in the art will understand that
many combinations of deletions, insertions, inversions and substitutions can be made within the
anakinra amino acid sequence, provided that the resulting molecule (“the anakinra variant”) is
biologically active, e.g. possesses the ability to inhibit IL-1. Particular anakinra variants are
described in e.g. U.S. Patent Nos. 5,075,222; 6,858,409 and 6,599,873.
The term “anakinra” further includes fusion proteins comprising anakinra. Anakinra can be
formatted to have a larger hydrodynamic size, for example, by attachment of a
polyalkyleneglycol group (e.g. a polyethyleneglycol (PEG) group), serum albumin, transferrin,
transferrin receptor or at least the transferrin-binding portion thereof, an antibody Fc region, or
by conjugation to an antibody domain.
The term “an effective amount” refers to an amount that confers a therapeutic effect on the
treated subject. The therapeutic effect may be objective (i.e. measurable by some test or marker)
or subjective (i.e. the subject gives an indication of or feels an effect).
Preferably, anakinra is administered in a dose from 0.1 to 100 mg/kg per day, preferably 0.1 to 1
mg/kg per day. A preferred dosage for the treatment of IL-1 mediated diseases should produce
blood anakinra concentrations between 1 and 1000 ng/ml. Accordingly, it is preferred that,
initially, doses are administered to bring the circulating levels of anakinra above 5 ng per ml of
plasma.
The pharmaceutical formulation according to the invention preferably comprises anakinra in an
amount between 20 and 200 mg/ml, more preferably between 100 and 200 mg/ml, such as 150
mg/ml.
The pharmaceutical formulation according to the invention is adapted for subcutaneous injection
of anakinra. Preferably, the pharmaceutical formulation comprises a chelating agent, such as
ethylenediaminetetraacetic acid (EDTA). The amount of EDTA in the formulation is preferably
from 0.05 to 1 mM, more preferably around 0.5 mM. An emulsifier, preferably a non-ionic
surfactant such as polysorbate 80 (also known as polyoxyethylene sorbitan monooleate or Tween
80), can be added to the formulation to reduce aggregation and denaturation, as well as for
increased solubility. The amount of polysorbate 80 is preferably between 0.01 and 1%, more
preferably around 0.1%. Consequently, a preferred form of the pharmaceutical formulation
according to the invention comprises 150 mg/ml anakinra, 0.5 mM EDTA and 0.1% polysorbate
The pharmaceutical formulation of the invention comprises the tonicity agent mannitol in an
amount from 5 to 50 mg/ml. Formulations with mannitol at an amount of from 1 to 100 mg/ml
are also described.
The pharmaceutical formulation according to the invention can comprise a second tonicity agent,
e.g. NaCl, in an amount sufficient to provide isotonicity of the formulation. A preferred tonicity
agent is NaCl in a concentration between 120 and 240 mM, preferably about 120-180 mM, such
as about 120-150 mM, or most preferably around 140 mM.
Alternatively, the said tonicity agent can be a mixture of NaCl and a third tonicity agent selected
from the group consisting of monosaccharides, disaccharides and sugar alcohols. Preferably, the
third tonicity agent is selected from the group consisting of sucrose, sorbitol, glycerol, inositol,
and trehalose. More preferably, the third tonicity agent is sorbitol or glycerol.
The invention includes pharmaceutical formulations wherein the active protein, i.e. anakinra, is
sufficient as a buffering substance and capable of maintaining the pH at a desired level,
preferably about pH 6.5. Consequently, no additional buffering substance has to be added to the
formulation according to the invention. However, included in the invention are also
pharmaceutical formulations comprising anakinra and at least one additional buffering substance,
provided that the said additional buffering substance is not a citrate buffer. The said additional
buffering substance can for instance be a phosphate buffer, or histidine. More specifically, the
said additional buffer could be sodium phosphate in an amount of 1 to 50 mM, preferably around
mM, or histidine in an amount of 5 to 50 mM, preferably around 10 mM.
Particularly preferred formulations are those comprising a phosphate buffer in combination with
mannitol. In such formulations, the concentration of phosphate, such as sodium phosphate, is
preferably from 1 to 50 mM (more preferably around 10 mM) and the mannitol concentration is
preferably from 5 to 50 mg/ml (more preferably around 10 mg/ml). The pH of the said
formulation is preferably between 6 and 7, such as between 6.3 and 6.6, or more preferably
around 6.5.
Consequently, preferred formulations according to the invention include formulations
comprising:
(a) anakinra (100 – 200 mg/ml):
(b) EDTA (0.05 – 1 mM);
(c) polysorbate 80 (0.01 – 1 %);
(d) NaCl (120 – 180 mM);
(e) sodium phosphate, pH 6 – 7 (1 – 50 mM); and
(d) mannitol (5 – 50 mg/ml).
A particularly preferred formulation comprises:
(a) anakinra (150 mg/ml):
(b) EDTA (0.5 mM);
(c) Polysorbate 80 (0.1%);
(d) NaCl (120 – 150 mM, preferably 140 mM);
(e) sodium phosphate, pH 6.3 – 6.6, preferably pH 6.5 (10 mM); and
(d) mannitol (10 mg/ml).
The pharmaceutical formulation according to the invention can preferably be used in the
treatment of at least one IL-1 mediated disorder. Also described is a method for the treatment of
an IL-1 mediated disorder, comprising administering to a mammal, including humans, in need of
such treatment a pharmaceutical formulation as defined herein. The term “treatment” includes
prevention (prophylaxis) of IL-1 mediated disorders, or amelioration or elimination of the
disorder once it has been established.
A disease or medical condition is considered to be an “IL-1 mediated disorder” if the
spontaneous or experimental disease or medical condition is associated with elevated levels of
IL-1 in bodily fluids or tissue or if cells or tissues taken from the body produce elevated levels of
IL-1 in culture. In many cases, such interleukin-1 mediated diseases are also recognized by the
following additional two conditions: (1) pathological findings associated with the disease or
medical condition can be mimicked experimentally in animals by the administration of IL-1; and
(2) the pathology induced in experimental animal models of the disease or medical condition can
be inhibited or abolished by treatment with agents which inhibit the action of IL-1. In most
interleukin-1 mediated diseases at least two of the three conditions are met, and in many
interleukin-1 mediated diseases all three conditions are met.
IL-1 mediated disorders include:
• Amyloid A amyloidosis
• Adult onset Still’s disease (AOSD)
• Asthma
• Behçet’s disease
• Blau syndrome
• Cachexia
• Calcium pyrophosphate dihydrate disease (CPPD)
• Castleman’s disease
• Cryopyrin-associated periodic syndromes (CAPS)
• Deficiency of the interleukinreceptor antagonist (DIRA)
• Dermatomyositis
• Erdheim-Chester’s disease
• Erosive osteoarthritis
• Familial Mediterranean fever
• Generalised pustular psoriasis
• Gout and pseudogout
• Graft vs. host disease
• Hidradenitis Suppurativa
• Hyper IgD syndrome (HIDS)
• Idiopathic cold urticaria
• Inclusion-body myositis
• Inflammatory bowel disease (IBD)
• Ischemic injury
• Macrophage Activation Syndrome
• Majeed syndrome
• Mevalonate kinase deficiency
• Myelogenous and other leukemias,
• Neutrophilic panniculitis
• Osteoporosis
• Periodic fevers with aphthous stomatitis, pharyngitis, and adenitis (PFAPA)
• Polymyositis
• Psoriasis
• Pyoderma gangrenosum, acne conglobata, and aseptic arthritis (PAPA)
• Recurrent idiopathic pericarditis
• Relapsing polychondritis
• Reperfusion injury
• Rheumatoid arthritis (RA)
• Schnitzler's syndrome
• Sepsis; sepsis syndrome
• Smoldering myeloma
• Synovitis Acne Pustulosis Hyperostosis Osteitis (SAPHO) syndrome
• Systemic onset idiopathic juvenile arthritis (SoIJA)
• Tumour necrosis factor receptor–associated periodic syndrome (TRAPS)
• Type 1 diabetes
• Type 2 diabetes
• Urticarial vasculitis
• Uveitis
In a preferred form of the invention, the pharmaceutical formulation is administered by
subcutaneous injection to a mammal, including humans, in need thereof. According to the
invention, nociceptive pain at the site of subcutaneous injection is avoided or reduced. The term
“nociceptive pain” implies neural activity initiated by nociceptors (pain receptors).
The term “comprising” as used in this specification means “consisting at least in part of”. When
interpreting each statement in this specification that includes the term “comprising”, features
other than that or those prefaced by the term may also be present. Related terms such as
“comprise” and “comprises” are to be interpreted in the same manner.
EXAMPLES
EXAMPLE 1: Stability with respect to visible aggregation
Frozen anakinra bulk solution in 10 mM sodium citrate, 140 mM NaCl and 0.5 mM EDTA,
obtained from Amgen Manufacturing, was thawed and diafiltrated using a Millipore ProFlux
M12 system, including a 0.1 m Millipore Pellicon 2 Mini cassette, having a 10 kDa composite
regenerated cellulose PLC10 membrane (www.millipore.com). The obtained solutions were
concentrated by Ultra filtration in according to standard methods.
The compositions described in Table I were prepared from the obtained diafiltered and
concentrated solutions above. In addition to the ingredients shown in Table I, all compositions
contained 150 mg/ml anakinra, 0.5 mM EDTA and 0.1 % polysorbate 80. The solutions were
filled in siliconized glass syringes (1 ml) which were stored for 1 month (+5°C or +25°C) or for
3 months (+5°C).
Table I: Investigated anakinra compositions
Composition NaCl (mM) Buffer (10 mM) pH
E 120 Sodium citrate 6.2
G 120 Sodium phosphate 6.2
H 120 Histidine 6.2
O 120 – 6.5
R 120 Sodium citrate 6.5
S 240 Sodium citrate 6.5
T 120 Sodium phosphate 6.5
U 120 Sodium phosphate 6.8
The solutions in Table I were tested for subvisible particles by a light blockage technique
according to United States Pharmacopeia – National Formulary (USP–NF), Chapter 905
(www.usp.org) but adjusted to a small sample volume. At each time point samples from 3
syringes were pooled and tested. In each pool, the number of particles larger than 5, 7.5 and 10
µm in size was determined. The results are shown in Table II and Figures 1-3. Typical results for
subvisible particles in parenteral products are in the range of less than 6000 particles larger than
µm.
Table II: Subvisible particles in anakinra formulations
Start 1 month 1 month 3 months
+5°C +25°C +5°C
Composition Particles (>5 μm)/ml
E 221 282 562 477
G 229 113 270 324
H 162 323 418 476
O 223 249 386 584
R 270 528 771 373
S 136 266 524 421
T 272 451 517 533
U 154 456 468 549
The measured amount of subvisible particles indicates that the visible aggregation of anakinra is
relatively low, increases slightly over time, and is not dependent on presence of buffer. The data
demonstrates that anakinra can be formulated without sodium citrate and with equivalent
stability.
EXAMPLE 2: Aggregation stability
Anakinra compositions were prepared and stored as described in Example 1. The monomer
content was measured by Size Exclusion Chromatography (SEC). Each sample was diluted with
a 10 mM sodium citrate, 140 mM NaCl, 0.5 mM EDTA to an anakinra concentration of 5
mg/mL. The diluted sample was loaded on a TSK-Gel G2000 SWXL Column, 7.8 mm x 30 cm
(ToSoh Biosciences 08450) and eluted with a 10 mM sodium citrate, 140 mM NaCl and 0.5 mM
EDTA at a flow of 0.5 mL/min. The absorbance at 280 nm was recorded and the % monomer
was calculated from the respective peak area.
The results (Table III) show that the level of anakinra monomer remained stable for 3 months in
all studied anakinra compositions.
Table III: Stability of various anakinra formulations
Start 1 month 1 month 3 months
+5°C +25°C +5°C
Composition % monomer by SEC
E 99.8 99.8 99.2 99.7
G 99.9 99.8 99.1 99.7
H 99.8 99.8 99.1 99.7
O 99.9 99.8 99.0 99.7
R 99.8 99.8 99.0 99.7
S 99.9 99.8 99.2 99.7
T 99.9 99.8 98.7 99.7
U 99.8 99.8 98.6 99.6
EXAMPLE 3: pH stability
Anakinra compositions were prepared and stored as described in Example 1. pH was measured
according to standard procedures. The results (Table IV) show that pH remained stable for 3
months in all studied anakinra compositions.
Table IV: pH stability of various anakinra formulations
Start 1 month 1 month 3 months
+5°C +25°C +5°C
Composition pH
E 6.1 6.1 6.1 6.1
G 6.1 6.0 6.0 6.1
H 6.1 6.1 6.1 6.2
O 6.1 6.0 6.0 6.1
R 6.2 6.2 6.2 6.2
S 6.1 6.0 6.0 6.1
T 6.4 6.4 6.4 6.5
U 6.7 6.7 6.7 6.7
EXAMPLE 4: Stability of anakinra compositions comprising phosphate and mannitol
Frozen anakinra bulk solution in 10 mM sodium citrate, 140 mM NaCl and 0.5 mM EDTA,
obtained in-house, was thawed and diafiltrated using a Millipore ProFlux M12 system,
including a 0.1 m Millipore Pellicon 2 Mini cassette, having a 10 kDa composite regenerated
cellulose PLC10 membrane (www.millipore.com). The obtained solutions were concentrated
by Ultra filtration in according to standard methods.
The compositions described in Table V were prepared from the obtained diafiltered and
concentrated solutions above. In addition to the ingredients shown in Table V, all compositions
contained 150 mg/ml anakinra. The solutions were filled in siliconized glass syringes (1 ml)
which were stored at different temperatures to test the stability of anakinra in these formulations.
The samples were stored for 1 month at +30°C, 2 and 4 months at +25°C.
Table V: Investigated anakinra compositions
Composition NaCl Buffer Mannitol Polysorbate EDTA pH
(mM) 80
A 145 10 mM Sodium 0 (0.1%) 0.5 mM 6.3
citrate
C 145 10 mM Sodium 10 mg/mL (0.1%) 0.5 mM 6.3
phosphate
D 145 10 mM Sodium 0 (0.1%) 0.5 mM 6.3
phosphate
D2 145 10 mM Sodium 10 mg/mL (0.01%) 0.1 mM 6.3
phosphate
The monomer content was measured by Size Exclusion Chromatography (SEC) after storage at
each temperature. Each sample was diluted with a 10 mM sodium citrate, 140 mM NaCl, 0.5
mM EDTA to an anakinra concentration of 5 mg/mL. The diluted sample was loaded on a TSK-
Gel G2000 SWXL Column, 7.8 mm x 30 cm (ToSoh Biosciences 08450) and eluted with a 10
mM sodium citrate, 140 mM NaCl and 0.5 mM EDTA at a flow of 0.5 mL/min. The absorbance
at 280 nm was recorded and the % monomer was calculated from the respective peak area. The
results of the Size Exclusion Chromatography (SEC) analysis presented in Table VI show that
the level of anakinra monomer remained stable for up to 4 months in all studied anakinra
compositions.
Table VI: Stability of the investigated anakinra formulations
Start 1 month 2 months 4 months
+30°C +25°C +25°C
Composition % monomer by SEC
A 99.8 95.3 96.8 92.9
C 99.8 95.5 96.9 93.1
D 99.8 95.0 96.6 92.3
D2 99.8 95.7 97.0 93.2
Furthermore, proteins such as anakinra are typically sensitive to changes in pH. To evaluate any
effect of pH on anakinra in the performed studies were the pH values in the formulations
recorded. The results are shown in Table VII and show an increase in pH over time but this
change is independent of formulation and the exhibited differences in monomer content in Table
VI is not caused by a difference in pH.
Table VII: Solution pH of the investigated anakinra formulations
Start 1 month 2 months 6 months
+30°C +25°C +5°C
Composition pH
A 6.3 6.3 6.5 6.5
C 6.3 6.3 6.5 6.4
D 6.3 6.3 6.5 6.5
D2 6.3 6.3 6.5 6.5
EXAMPLE 5: Effect of anakinra compositions in Hargreaves test
The aim of these studies was to compare the effect of different formulations of anakinra (citrate
buffer or phosphate/mannitol buffer) on thermal nociception threshold and hind paw volume in
male Sprague-Dawley rats (Hargreaves et al, 1988).
Intraplantar administration of histamine (50 µl/paw, 3 mg/ml), citrate buffer (10 mM pH 6.3) or
phosphate buffer (10 mM, pH 6.3, plus mannitol 10 mg/ml) with or without anakinra (150
mg/ml), was made in the in right hind paw. Oedema formation, measured as an increase in paw
volume after 2 hours indicated that citrate buffer and citrate buffered anakinra as well as
phosphate/mannitol buffered anakinra caused acute inflammation (Fig 4). Phosphate/mannitol
buffer did not cause acute inflammation. Histamine (0.15 mg/paw), used as a positive control,
induced thermal hyperalgesia and oedema formation.
In conclusion, there was a clear difference in paw swelling after 2h between citrate buffer and
phosphate/mannitol buffer alone. Additionally, paw volume measurements 2h after injection
showed a tendency for phosphate/mannitol-buffered anakinra to cause less oedema formation
compared to citrate-buffered anakinra.
EXAMPLE 6: Effect of anakinra compositions on Evans Blue permeability in rats
Male rats are anaesthetized with isoflurane, and the fur on the back and sides is carefully shaved
away with clippers, carefully avoiding traumatization. A grid with 8 squares is drawn on the
exposed skin on the back and sides with a marking pen. Evans Blue solution (1 mg/kg; Sigma-
Aldrich) is administered by injection into the lateral tail vein, prior to subcutaneous injection of
anakinra test solutions (1000 μl) in a random pattern within the grid squares. After the injection,
the animals are returned into their cages and allowed to recover from anaesthesia. 6 hours after
injection, the animals are euthanized by exposure to carbon dioxide. The skin is removed from
the back and cleaned from adipose and connective tissue, and mounted on a board with the furry
side down. The size of the zone of extravased Evans Blue dye in millimeters is measured by a
centimeter ruler, and a subjective score ranging from 0 to 4 is assigned to the extravasation
reaction, based on the intensity of dye staining.
Various anakinra compositions, including anakinra in “CSEP” (10 mM sodium citrate; 0.5 mM
EDTA, 0.1% polysorbate 80, and 140 mM NaCl, pH 6.5), as well as phosphate buffered saline
(PBS) as a control, are administered. The measured permeability changes indicate that injection
of 1 ml PBS alone results in only minor leakage of Evans Blue dye from the site of injection. In
contrast, injection of anakinra, dissolved at 100 mg/ml in CSEP, strongly increases permeability.
EXAMPLE 7: Effect of anakinra compositions on mouse nociceptive behavior
In order to assess the algesiogenic action of different anakinra compositions at the site of
injection, the mouse hind paw licking model (Piovezan et al., 1998) is used. The animals are
placed individually in chambers (transparent glass cylinders) and are acclimatized for at least 20
min before sub-plantar injection of various test anakinra compositions, including anakinra in
CSEP (see Example 6) as well as PBS as a control. After challenge, the mice are observed
individually for 15-30 min. The amount of time spent licking the injected paw is measured with a
stop watch and is considered as indicative of nociceptive behavior.
EXAMPLE 8: Effect of anakinra compositions in hot plate test
In order to assess the algesiogenic actions of different anakinra compositions at the site of
injection, the mouse thermal hyperalgesia model (Kanaan et al., 1996) is used. Animals are
acclimatized to a hot plate instrument (Ugo Basil, Italy), preheated to 30°C, 1-2 days before
testing. On the day of testing, animals receive sub-plantar injection of various test anakinra
compositions, including anakinra in CSEP (see Example 6) as well as PBS as a control. With the
experimenter blind to the treatment, mice are tested on the hot plate set to +52°C. Response
latency is determined as the time taken to lick a hind paw or jump.
EXAMPLE 9: Effect of different anakinra formulations on mast cell degranulation, in vitro
A23187 (a calcium ionophore) and dose-response IgE-anti-IgE serve as positive controls for
mast cell activation. Mast cells from 10 different individuals (5 from cord blood and 5 from adult
individuals) are isolated. The mast cells are isolated through CD34-selection (flow cytometry) of
hematopoietic cells, which are subsequently grown at 37°C, 5% CO under serum-deprived
conditions, in the presence of human recombinant stem cell factor (Stemgen®) and IL-6 during
6-8 weeks (Gulliksson, M. et al., 2010). The degree of mast cell degranulation, after subjecting
the cells to the different anakinra formulations, is assessed through measurements of histamine
and PGD2. A change in mast cell degranulation is a measure of an alteration in the activation
levels of the mast cells, which is a marker for the mechanisms of the acute inflammatory pain.
EXAMPLE 10: Effect of subcutaneous anakinra compositions on extracellular pain mediators
release at the site of injection using microdialysis method
To investigate the acute effect of injection of various anakinra compositions including anakinra
in CSEP (see Example 6) as well as PBS as a control, a well known microdialysis method for
determination of extracellular concentrations of biochemical pain mediators (e.g.
neurotransmitters, neuromodulators, and acute inflammatory cytokine and chemokine) is used.
Animals are anaesthetized by inhalation of isoflourane during the experiment. The microdialysis
probe is inserted into the dermis of the skin at the upper neck of each animal. The inlet tubing of
the microdialysis probe is connected to a microinfusion pump and a Krebs-Ringer solution is be
pumped at a flow rate of 1-10 ml/min. The samples are collected and the pain mediator is
analyzed (e.g by ELISA) for each individual experiment (Weidner C., et al., 2000 and Yoshitake
T. et al., 2012).
REFERENCES
• Bedele A., Colloton M., Vrkljan M., Morris J and Sabados K. (1995): Cutaneous mast
cell degranulation in rats receiving injections of recombinant human interleukin-1
receptor antagonist (rhIL-1ra) and/or its vehicle: Possible clinical implications. J. Lab.
Clin. Med. 125: 493-500.
• Fransson J. and Espander-Jansson A. (1996): Local tolerance of subcutaneous injections.
J. Pharm. Pharmacol. 48: 1012–1015.
• Frenken, L.A., van Lier, H.J., Jordans, J.G., Leunissen, K.M., van Leusen, R.,
Verstappen, V.M., Koene, R.A. (1993): Identification of the component part in an epoetin
alfa preparation that causes pain after subcutaneous injection. Am. J. Kidney Dis. 22: 553-
556.
• Gulliksson, M. et al. (2010) Mast cell survival and mediator secretion in response to
hypoxia. PLoS One 5(8):e12360.
• Haller C., Cosenza M. and Sullivan J. (2008): Safety Issues Specific to Clinical
Development of Protein Therapeutics. Clin Pharmacol Ther. 84(5): 624-627.
• Hargreaves K. et al. (1988): A new and sensitive method for measuring thermal
nociception in cutaneous hyperalgesia. Pain 32: 77-88.
• Kanaan S.A. et al: (1996): Endotoxin-induced local inflammation and hyperalgesia in rats
and mice: a new model for inflammatory pain. Pain 66: 373-379.
• Laursen T., Hansen B and Fisker S. (2006): Pain Perception after Subcutaneous
Injections of Media Containing Different Buffers. Basic & Clinical Pharmacology &
Toxicology 98: 218–221.
• Nema S., Brendel R. and Washkuhn R.: Excipients: Parenteral Dosage Forms and Their
Role. In: Swarbrick, J. (Ed.) Encyclopedia of Pharmaceutical Technology, third edition.
Informa Healthcare, 2006.
• Piovezan A.P. et al. (1998): Effects of endothelin-1 on capsaicin-induced nociception in
mice. European Journal of Pharmacology 351: 15-22
• Raibekas A, Bures E., Siska C., Kohno T., Latypov R. and Kerwin B. (2005): Anion
Binding and Controlled Aggregation of Human Interleukin-1 Receptor Antagonist.
Biochemistry 44: 9871-9879.
• Thaler K., Chandiramani D., Hansen R., and Gartlehner G. (2009): Efficacy and safety of
anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug
Effectiveness Review Project. Biologics 3: 485–498.
• Wang J., Kowall R. (1980): Review of excipients and pH’s for parenteral products used
in the United States. Journal of Parenteral Drugs 34: 452-462.
• Winder C., et al. (2000): Acute effect of substance P and calcitonin gene-related peptide
in human skin – A microdialysis study. The Journal of Investigative Dermatology. 115:
1015-1020.
• Yoshitake T., et al. (2012): Determination of histamine in microdialysis samples from
Guinea pig skin by high-performance liquid chromatography with fluorescence detection.
Skin Pharmacology Physiology 25:65–72.
Claims (26)
1. A pharmaceutical formulation suitable for injection comprising an effective amount of anakinra, and mannitol in an amount from 5 to 50 mg/ml, wherein the said pharmaceutical 5 formulation is in the absence of citrate.
2. The pharmaceutical formulation according to claim 1 which is adapted for subcutaneous injection of anakinra. 10
3. The pharmaceutical formulation according to claim 1 or 2, wherein the said effective amount of anakinra is between 20 and 200 mg/ml.
4. The pharmaceutical formulation according to any one of claims 1 to 3, additionally comprising a chelating agent.
5. The pharmaceutical formulation according to claim 4, wherein the said chelating agent is EDTA in an amount from 0.05 to 1 mM.
6. The pharmaceutical formulation according to any one of claims 1 to 5, additionally 20 comprising an emulsifier.
7. The pharmaceutical formulation according to claim 6, wherein the said emulsifier is the non-ionic surfactant Polysorbate 80 in an amount from 0.01 to 1 %. 25
8. The pharmaceutical formulation according to any one of claims 1 to 7, comprising 150 mg/ml anakinra, 0.5 mM EDTA and 0.1% polysorbate 80.
9. The pharmaceutical formulation according to any one of claims 1 to 8, in addition comprising a tonicity agent in an amount sufficient to provide isotonicity of the 30 formulation.
10. The pharmaceutical formulation according to claim 9, wherein the said tonicity agent is NaCl in an amount from 120 to 240 mM.
11. The pharmaceutical formulation according to claim 9, wherein the said tonicity agent is a mixture of NaCl and a second tonicity agent selected from the group consisting of monosaccharides, disaccharides and sugar alcohols. 5
12. The pharmaceutical formulation according to any one of claims 1 to 11, comprising no additional buffering substance.
13. The pharmaceutical formulation according to any one of claims 1 to 11, comprising at least one additional buffering substance, provided that the said additional buffering substance is 10 not a citrate buffer.
14. The pharmaceutical formulation according to claim 13, wherein the said additional buffering substance is phosphate in an amount from 1 to 50 mM.
15 15. The pharmaceutical formulation according to claim 14, comprising 10 mM phosphate and 10 mg/ml mannitol.
16. The pharmaceutical formulation according to claim 14, comprising: (a) anakinra (100 – 200 mg/ml): 20 (b) EDTA (0.05 – 1 mM); (c) polysorbate 80 (0.01 – 1 %); (d) NaCl (120 – 180 mM); (e) sodium phosphate, pH 6-7 (1 – 50 mM); (d) mannitol (5 – 50 mg/ml)
17. The pharmaceutical formulation according to claim 16, comprising: (a) anakinra (150 mg/ml): (b) EDTA (0.5 mM); (c) polysorbate 80 (0.1%); 30 (d) NaCl (145 mM); (e) sodium phosphate, pH 6.5 (10 mM); (d) mannitol (10 mg/ml)
18. The pharmaceutical formulation according to any one of claims 1 to 17 for use in the treatment of IL-1 mediated disorders.
19. The pharmaceutical formulation according to claim 18 wherein the said IL-1 mediated 5 disorder is rheumatoid arthritis.
20. The pharmaceutical formulation according to any one of claims 1 to 17, wherein nociceptive pain at the site of subcutaneous injection is avoided or reduced. 10
21. Use of anakinra and mannitol, in the manufacture of a pharmaceutical formulation suitable for injection for use in the treatment of IL-1 mediated disorders, wherein: said pharmaceutical formulation is in the absence of citrate; anakinra is present in the medicament in an effective amount; and mannitol is present in the medicament in an amount from 5 to 50 mg/ml.
22. Use of claim 21, wherein the pharmaceutical formulation is as defined in any one of claims 2 to 17.
23. Use of claim 21 or claim 22, wherein the said IL-1 mediated disorder is rheumatoid 20 arthritis.
24. Use of any one of claims 21 to 23, wherein nociceptive pain at the site of subcutaneous injection is avoided or reduced.
25 25. A pharmaceutical formulation suitable for injection as claimed in any one of claims 1 to 20, substantially as herein described with reference to any example thereof and with or without reference to the accompanying drawings.
26. Use as claimed in any one of claims 21 to 24, substantially as herein described with 30 reference to any example thereof and with or without reference to the accompanying drawings. 100 150 200 250 300 1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE1150109-5 | 2011-02-11 | ||
SE1150109 | 2011-02-11 | ||
PCT/SE2012/050124 WO2012108828A1 (en) | 2011-02-11 | 2012-02-09 | Citrate free pharmaceutical compositions comprising anakinra |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ613111A NZ613111A (en) | 2014-06-27 |
NZ613111B2 true NZ613111B2 (en) | 2014-09-30 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7159277B2 (en) | Rapid-acting insulin composition | |
EP3536380B1 (en) | Rapid-acting insulin compositions | |
ES2440289T3 (en) | Preparation comprising insulin, nicotinamide and arginine | |
US10179162B2 (en) | Citrate free pharmaceutical compositions comprising anakinra | |
US20220339252A1 (en) | Topical erythropoietin formulations and methods for improving wound healing with and cosmetic use of the formulations | |
WO2019008033A1 (en) | Methods and medical uses relating to the treatment of hypoglycaemia | |
US20180236079A1 (en) | Stabilized glucagon solutions | |
JP6943858B2 (en) | Collagen 7 composition and method using it | |
NZ613111B2 (en) | Citrate free pharmaceutical compositions comprising anakinra | |
RU2777367C2 (en) | Local erythropoietin compositions, methods for improvement of wound healing, and cosmetic use of compositions |